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Background: Increased infection caused by multidrug resistant (MDR) Pseudomonas aeruginosa has raised
awareness of the resistance situation worldwide. Carbapenem resistance among MDR (CR-MDR) P. aeruginosa has
become a serious life-threatening problem due to the limited therapeutic options. Therefore, the objectives of
this study were to determine the prevalence, the antibiotic susceptibility patterns and the relatedness of CR-MDR
P. aeruginosa in tertiary hospitals across Thailand.
Methods: MDR P. aeruginosa from eight tertiary hospitals across Thailand were collected from 2007–2009.
Susceptibility of P. aeruginosa clinical isolates was determined according to the Clinical and Laboratory Standards
Institute guideline. Selected CR-MDR P. aeruginosa isolates were genetically analyzed by pulsed-field gel
electrophoresis.
Results: About 261 clinical isolates were identified as MDR P. aeruginosa and approximately 71.65% were found
to be CR-MDR P. aeruginosa. The result showed that the meropenem resistance rate was the highest reaching
over 50% in every hospitals. Additionally, the type of hospitals was a major factor affecting the resistance rate,
as demonstrated by significantly higher CR-MDR rates among university and regional hospitals. The fingerprinting
map identified 107 clones with at least 95% similarity. Only 4 clones were detected in more than one hospital.
Conclusions: Although the antibiotic resistance rate was high, the spreading of CR-MDR was found locally.
Specific strains of CR-MDR did not commonly spread from one hospital to another. Importantly, clonal
dissemination ratio indicated limited intra-hospital transmission in Thailand.
Keywords: Antimicrobial susceptibility, Pulsed-field gel electrophoresis, Carbapenem resistance, Multidrug
resistance, Pseudomonas aeruginosa, EpidemiologyIntroduction
Overuse of antibiotics in a hospital can cause a selective
pressure on microorganisms, which in turn, can enhance
the antimicrobial resistance in bacteria. Inappropriate use
of antibiotics has been reported to be involved in increas-
ing the antibiotic resistance [1,2]. This circumstance* Correspondence: mullika.tra@mahidol.ac.th
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distribution, and reproduction in any mediumbecomes a major concern in Thailand, especially in uni-
versity hospitals [3].
Among hospital-acquired microorganisms, Pseudo-
monas aeruginosa, a non-fermentative, gram-negative
bacterium, is one of the most common causative agents
in nosocomial infections. According to the NNISS report
(National Nosocomial Infections Surveillance System
in United States) and INICC (International Nosocomial
Infection Control Consortium), P. aeruginosa is the most
common pathogen found in intensive care units from
the respiratory tract and central line-associated primaryCentral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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the SENTRY program in Latin American during
1997–2000 showed that P. aeruginosa was the most com-
monly isolated pathogen from hospitalized pneumonia
patients and had high resistance rates for most of tested
antimicrobials [7]. In Thailand, like other parts of the
world, P. aeruginosa has been shown to have the highest
prevalence rate along with its intrinsic antibiotic resistance
mechanisms [8,9]. Infections caused by multidrug resist-
ant (MDR) P. aeruginosa can lead to serious outcomes
such as amputation or in the worst case, death [10].
The mortality rate of MDR P. aeruginosa infections was
significantly higher than infections caused by susceptible
P. aeruginosa [11]. In the US surveillance study, MDR
P. aeruginosa rate was found to increase from 4% to 14%
over the period of 1993 to 2002 [4].
Carbapenem, a member of the β-lactam family, has
a broad spectrum of activity and is stable to most β-
lactamases. These properties make carbapenem to be
important therapeutic options for treating serious infec-
tions involving resistant strains of Enterobacteriaceae,
anaerobes, P. aeruginosa, and Acinetobacter spp. [12,13].
Carbapenem has always been chosen as the first option
for initial empirical treatment in many severe infections,
e.g. nosocomial pneumonia, and chronic MDR pseudo-
monal infections [12,14]. Although carbapenem is a very
powerful antibiotics, the resistance rate is still increas-
ing [15].
Although carbapenem resistance (CR) has been widely
studied, there is limited information on the CR rates
among MDR (CR-MDR) bacterial pathogens. These
situations raised the question, “How many P. aeruginosa
isolates in Thailand are CR-MDR?” Therefore, the objec-
tives of this study were to determine (i) the prevalence
of CR-MDR P. aeruginosa in Thailand, (ii) the antibiotic
susceptibility patterns of CR-MDR P. aeruginosa, and
(iii) the relatedness of CR-MDR P. aeruginosa clinical
isolates across tertiary hospitals in Thailand. This study
would provide the first update report on an epidemi-
ology of CR-MDR P. aeruginosa in Thailand.
Materials and methods
Bacterial collection
P. aeruginosa clinical isolates were collected from eight
hospitals from 2007 to 2009 within five regions of
Thailand. The study was complied with International
Guidelines for Human Research Protection and was
approved by Mahidol University Institutional Review
Board (MU-IRB) under the certificate of approval No.
MU-IRB 2011/025.0102. All participated hospitals are
tertiary hospitals. Four hospitals are regional hospitals
and the other four hospitals are university hospitals. Re-
gional hospitals located in province centers have a cap-
acity for at least 500 beds, while university hospitals areteaching schools which also provide postgraduate and
specialist programs. Both hospitals have a comprehen-
sive set of specialists and have been transferred patients
from primary and secondary hospitals in their regions.
However, rare condition treatments or patients with high
complexity mostly have been transferred to university
hospitals. Bacterial clinical isolates were identified and
performed susceptibility test by the hospital’s laboratory
technicians using their standard hospital procedures.
Multidrug resistance criteria in this study were defined
as non-susceptible to at least 3 of 5 drug groups, includ-
ing the anti-pseudomonal penicillins, cephalosporins,
aminoglycosides, fluoroquinolones and carbapenem [16].
Bacterial strains were cultured in triple sugar iron agar
(BD, Sparks, MD, USA) and stored at 4°C before being
submitted to the research laboratory. All bacteria clinical
isolates were enriched before storage at −80°C. Cetri-
mide agar (BD, Sparks, MD, USA) supplement with 10%
glycerol was used as the selective minimal medium to
confirm isolates as P. aeruginosa.
Antibiotic susceptibility test
The susceptibility of P. aeruginosa clinical isolates was
confirmed in the research laboratory by the disc diffu-
sion method according to the Clinical and Laboratory
Standards Institute (CLSI) guidelines [17]. All antibiotic
discs in this study included piperacillin (PIP), cef-
tazidime (CTZ), ciprofloxacin (CIP), gentamicin (CN),
imipenem (IMP), meropenem (MEM), and doripenem
(DOR) were purchased from Oxoid (Hants, UK). Anti-
biotic discs were placed onto the inoculated Mueller
Hinton agar (BD). After 37°C incubation overnight,
inhibition zones were measured and compared to CLSI
guidelines [18]. Imipenem and meropenem zone diam-
eter breakpoints were applied to doripenem since the
CLSI official zone diameter breakpoints for doripenem
were unavailable. Carbapenem resistance was defined by
being non-susceptible to at least 1 of the 3 carbapenem
tested. Among MDR P. aeruginosa clinical isolates, those
that were also CR were selected for study.
Genotyping by pulsed-field Gel electrophoresis
All selected CR-MDR P. aeruginosa clinical isolates were
analyzed by pulsed-field gel electrophoresis (PFGE)
using CHEF Mapper XA system (Bio-Rad, Hercules, CA,
USA). PFGE plugs were prepared according to Romling
et al. with some modifications [19]. The genotyping pat-
terns were confirmed for the relatedness of bacterial iso-
lates by Fingerprinting II InformatixTM software version
3.0 (Bio-Rad). A dendrogram was generated by the
unweighted-pair group method. The correlation between
band patterns was calculated with dice coefficient. Dif-
ferent clones were considered, if the percentage of simi-
larity was less than 95% [20]. The clonal dissemination
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MDR P. aeruginosa divided by number of selected
clones. Selected clones found in more than one hospital
were counted in every hospital. The clonal dissemination
ratio was indicated intra-hospital transmission.
Statistical analysis
Statistical analysis was compared between two groups by
Student t-test. A p-value of <0.05 was considered statis-




Two-hundred and sixty-one clinical isolates from eight
tertiary hospitals across Thailand were selected as MDR
P. aeruginosa. Antibiotic resistance rates of MDR P. aer-
uginosa in each hospital were shown in Table 1. Ceftazi-
dime demonstrated the highest resistance rate of about
95.79%, followed by ciprofloxacin and gentamicin which
were 92.34% and 87.36% resistance, respectively. The
carbapenem resistance rate among MDR P. aeruginosa
isolates was the highest for meropenem (about 65.52%)
and the resistance rates for imipenem and doripenem
were about 44.44% and 36.02%, respectively. It was note-
worthy that meropenem resistance was found at least
50% in all hospitals. Furthermore, resistance rates of car-
bapenem, unlike resistances for other drugs analyzed,
were found to be statistically greater (p < 0.05) between a
university hospital and a regional hospital.
Additionally, one-hundred and eighty-seven isolates
were determined to be CR-MDR P. aeruginosa. An aver-
age percentage of CR-MDR compared to MDR P. aeru-
ginosa was found to be very high, that is 70.49% with a
range of 58.33% to 83.67% (Table 2). The type of a hos-
pital was a major factor affecting the resistance rate as
demonstrated by significantly higher CR-MDR rates
(p < 0.05) among university hospitals and regional hospi-
tals. However, the region where a hospital located was
not observed to be a significant determining factor.Table 1 Drug resistance rates of MDR P. aeruginosa in particip
Size of Hospital Region of Thailand Hospital IMP (%)









PIP, piperacillin; CTZ, ceftazidime; CIP, ciprofloxacin; CN, gentamicin; IMP, imipenemMoreover, among CR-MDR P. aeruginosa, there was no
isolates resistant to only doripenem and only one isolate
showed double resistance to imipenem and doripenem.
Pulsed-field Gel electrophoresis
One-hundred and eighty-seven strains of CR-MDR P.
aeruginosa were analyzed by pulsed-field gel electro-
phoresis and 107 clones were identified as having 95%
similarity (Figure 1). Only 4 clones from 107 clones were
detected in more than one hospital (Table 2). Two
clones isolated from hospitals of the same region were
found to be related. Another clone was found related in
hospitals from two separate regions. The last clone was
found in three hospitals that were located in three sepa-
rated regions. Furthermore, the clonal dissemination
ratio of higher than 2.0 was found in two hospitals
in which the isolates were highly dominated at about 9
isolates per clone. (Table 2)
Discussions
The multidrug resistance of microorganisms has become
the critical problem in nosocomial infections, especially
P. aeruginosa and Acinetobacter spp. Both pathogens
have been listed in six famous ESKAPE pathogens (En-
terococcus faecium, Staphylococcus aureus, Klebsiella
pneumoniae, Acinetobacter species, Pseudomonas aeru-
ginosa, and Enterobacter species) and identified as the
most emerging threats in this century [21]. Antimicro-
bial resistance surveillance, has been performed in
almost every countries to identify the major problem
in nosocomial infections. This study provides the first
update data on the genetic relatedness of CR-MDR
P. aeruginosa clinical isolates from tertiary hospitals
across Thailand.
Antimicrobial resistance surveillance studies have been
observed in many countries throughout the world. Most
of these studies also determined carbapenem resistance
rates which described higher resistance rate for imipe-
nem than for meropenem [15,22-24]. However, the
Thailand national surveillance during 2000–2005 byated hospitals
MEM (%) DOR (%) PIP (%) CTZ (%) CIP (%) CN (%)
73.08 19.23 88.46 88.46 88.46 88.46
77.55 61.22 67.35 100.00 97.96 71.43
80.49 56.10 39.02 100.00 100.00 100.00
61.90 42.86 61.90 100.00 95.24 100.00
51.16 32.56 76.74 100.00 88.37 95.35
50.00 20.83 83.33 95.83 91.67 75.00
56.67 0.00 100.00 80.00 73.33 76.67
62.96 29.63 85.19 96.30 100.00 96.30
65.52 36.02 73.18 95.79 92.34 87.36
; MEM, meropenem; DOR, doripenem.
Table 2 CR-MDR ratio, clonal dissemination and clone number analyzed by PFGE in participated hospitals














(amount of existing clones)
University Hospital Central UC 26 21 80.77 17 1.24 18 (4), 8(2), 9, 11, 15, 16, 19, 44, 69, 73, 87, 94,
95, 98, 102, 105, 106
Northeast UNE 49 41 83.67 20 2.05 35(9), 45(5), 53(3), 65(3), 84(3), 83(2), 86(2), 89(2),
13, 41, 46, 50, 51, 54, 56, 62, 85, 88, 99, 107
North UN 41 34 82.93 18 1.89 90(6), 92(3), 20(3), 26(3), 28(3), 27(2), 30(2), 68(2),
12, 14, 21, 23, 24, 25, 29, 31, 91, 93
South US 21 15 71.43 11 1.36 10(3), 40(2), 41(2), 2, 17, 33, 42, 43, 52, 66, 70
Regional Hospital Northeast TNE 43 26 60.47 18 1.44 5(3), 7(3), 3(2), 4(2), 55(2), 79(2), 80(2),
6, 57, 75, 76, 77, 78, 82, 97, 101, 103, 104
South TS 24 14 58.33 10 1.40 32(2), 81(2), 1(2), 2(2), 33, 34, 48, 49, 72, 74
East TE1 30 19 63.33 10 1.90 62(4), 63(4), 58(2), 60(2), 64(2), 22, 39, 59, 67, 100
East TE2 27 17 62.96 8 2.13 36 (9), 47(2), 37, 38, 41, 61, 71, 96
MDR, multidrug resistant P. aeruginosa; CR-MDR, carbapenem resistance among multidrug-resistant P. aeruginosa; PFGE, Pulsed-field gel electrophoresis.
* underline indicated the selected clones which were found in more than one hospital.
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showed a slightly greater resistance rate for meropenem
than for imipenem [25]. Moreover, a recent study which
was conducted by Piyakul et al. in a tertiary hospital in
Thailand indicated that P. aeruginosa clinical isolates
exhibited a greater meropenem resistance rate than a
rate for imipenem [26]. In agreement with the study of
Piyakul et al., our data which analyzed MDR isolates of
P. aeruginosa, showed a greater difference of resistance
rates between meropenem and imipenem compared to
Piyakul et al. [26]. This difference might be caused by
the variety of the participated hospitals in the studies.
These studies indicated that carbapenem usage in Thailand
should be considered when drug susceptibility profile was
unavailable.
Although the carbapenem resistance rate in P. aerugi-
nosa or the MDR rate in P. aeruginosa is increasing, the
carbepenem resistance rate among MDR strains has sel-
dom been observed. The criteria for MDR P. aeruginosa
in the study of Sekiguchi et al. which was resistant to
imipenem, amikacin and ciprofloxacin was demonstrated
100% resistance rate to imipenem and meropenem and
more than 90% resistance to arbekacin, doripenem, and
aztreonam. Only resistances to polymyxin B and genta-
micin were found to be significantly lower, at about 28%
and 57.5%, respectively [27]. According to MDR criteria
in this study which was less stringent, antibiotic resist-
ance rates of MDR P. aeruginosa were higher than 50%
for most antibiotics. Only doripenem susceptibility was
found to be more than 60%. This lower resistance rate
might be because doripenem was recently approved
for use in Thailand. Interestingly, the overall resistance
rate of MDR P. aeruginosa in Thailand was found quite
high. These situations could urge an awareness of
limit antibiotic usage. Only recent launched antibiotic,doripenem, was showed the resistance rate less than
40%. Thus, highly concern should be recommended
especially in the strategy to prevent drug resistance emer-
ging and to preserve sensitivity of present antibiotics.
MDR P. aeruginosa is a life-threatening problem that
limits the use of critical antibiotics for treatment. The
ratio of CR-MDR among MDR isolated was very high in
hospitals, especially the university hospitals. The results
of the present study indicated that those hospitals, which
handled more complicated cases and thus employed
more complicated antibiotic treatments, could develop
more complicated drug resistance problems. Moreover,
inappropiate consumption of antibiotics has been a con-
cern in tertiary care hospitals and especially university
hospitals in Thailand [3]. High amounts of drug con-
sumption in a hospital can cause a selective pressure on
microorganisms resulting in increased drug resistance
[2]. This study reported significantly higher rate of CR-
MDR P. aeruginosa in university hospitals than regional
hospitals. Correlated with the study of Danchaivijitr
et al., the data showed that university hospitals had
greater consumption of carbapenem than regional hospi-
tals [8].
It was noteworthy that a single resistance of doripe-
nem in CR-MDR P. aeruginosa was not detected in this
study. This finding was correlated to lower MIC of dori-
penem compared to other carbapenem [28]. The doripe-
nem single resistance could be explained by the fact that
this drug was newly introduced to Thailand. This data
implied that resistance mechanisms for doripenem have
not yet been fully acquired by multidrug resistant
strains. Moreover, double resistance of imipenem and
doripenem was found in only one strain as compared to
double resistance of meropenem and doripenem which
could be detected in twenty-five strains. The well-known
Figure 1 A fingerprinting map showing the percentage of
similarity among 187 strains of CR-MDR P. aeruginosa.
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porins, increasing of efflux systems and enzyme degrad-
ation, were also reported to affect doripenem [29].
Metallo-beta-lactamases were reported to affect all car-
bapenem, but imipenem and meropenem had different
response to loss of oprD and efflux pump overexpression
[29]. Increasing the efflux pumps could mainly affect
both meropenem and doripenem, but not imipenem
[29,30]. However, some doripenem-resistant P. aerugi-
nosa clinical isolates have been found to lack functional
OprD [31]. The multiple resistances of CR-MDR P. aer-
uginosa suggested the possible use of polymyxin for
treatment. Although polymyxin remains active on the
CD-MDR strains, polymyxin is a drug with high nephro-
toxic side effect [32]. Our data suggested that treatment
with doripenem might be an optional treatment instead
of polymyxin to avoid side effect.
The PFGE results demonstrated a multiple DNA pat-
terns among the resistant strains [23]. One hundred and
seven clones were identified from 218 clinical isolates
indicating remarkable clonal diversity. Only 4 from 107
different clones were found to be inter-hospital trans-
mission. Two from four clones were detected in the
same region and only two clones were found in different
regions. Because of the difficulty in accessing patient his-
tories, the method of transmission between hospitals
could not be determined. There was a possibility that
infected patients were transferred between the hospitals.
The clonal dissemination ratio showed limited of inter-
hospital transmission. The ratio of higher than 2.0 was
found in two hospitals indicating that one clone was
infected in more than two patients. Additionally, these
hospitals were found dominant clones at about 9 isolates
per clone as showed in the Table 2. For other six hospi-
tals, the clonal dissemination showed that each patient
was infected by different clones indicating high variation
of CR-MDR P. aeruginosa. It was possible that high con-
sumption of antibiotic usage could provide high pressure
condition inducing mutation in bacteria.
The available results indicated that the high resistance
rate of MDR P. aeruginosa was localized and was due to
the antibiotic selection pressure. Antibiotic usage should
be carefully evaluated for its effect on the development
of bacterial resistance. Infectious Diseases Society of
America (IDSA) has presented guidelines for developing
an institutional program to enhance antibiotic steward-
ship [33]. The aim of the guidelines is to optimize anti-
biotic selection and usage while maximize the clinical
outcomes. Since our results indicated that Thailand
might have some patterns of resistance different from
that of other countries. Therapeutic options in Thailand
should be considered and adapted to minimize our re-
sistance problems. An appropriate adjustment of anti-
biotic usage should reduce the emergence of antibiotic
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existing and future antimicrobial agents [33,34].
Because CR-MDR P. aeruginosa infections are fre-
quently life-threatening, strategies to control the spread-
ing of antibiotic resistance phenomenon are necessary.
Our results showed that the spreading of CR-MDR in
Thailand was local, but the resistance rate of these
strains was high. The high consumption of antibiotics
might be a major problem. Therefore, antibiotic steward-
ship is one of the strategies that might help resolve the
problems. The effective strategies to control the muta-
tion of bacterial resistance are required to prevent the
spreading and also antibiotic strategy for treatment.
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